Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1988
Peer-review started: August 24, 2023
First decision: September 11, 2023
Revised: September 19, 2023
Accepted: September 27, 2023
Article in press: September 27, 2023
Published online: November 15, 2023
Processing time: 83 Days and 12 Hours
Gastric cancer (GC) is a malignant tumor with a high incidence and mortality rate worldwide for which acute bleeding is a common clinical complication.
Gastroscopic hemostasis is an important method for treating acute bleeding in GC; however, its efficacy and safety remain controversial.
This meta-analysis provides a wealth of evidence emphasizing the effectiveness and safety of endoscopic hemostasis for treating acute gastrointestinal bleeding in patients with GC.
Several databases was searched for related to gastroscopic hemostatic treatment for acute GC. The literature was screened according to the inclusion and exclusion criteria, data were extracted, and literature quality was evaluated. The meta-analysis was performed using RevMan software (version 5.3), while Begg’s test for publication bias was performed using Stata 13.0 software.
Compared with the control group, the hemostatic rate of gastroscopic hemostasis was increased [relative risk (RR) = 1.24; 95% confidence interval (CI) = 1.08-1.43; P = 0.003]; the rate of rebleeding (RR = 0.27; 95%CI: 0.09 to 0.80; P = 0.02), rate of surgery transfer (RR = 0.16; 95%CI: 0.06 to 0.43; P = 0.0003), serum C-reactive protein level [mean difference (MD) = -5.16; 95%CI: -6.11 to 4.21; P < 0.00001], interleukin-6 level (MD = -6.37; 95%CI: -10.33 to -2.42; P = 0.002), and tumor necrosis factor-α level (MD=-2.29; 95%CI: -4.06 to -0.52; P = 0.01) were decreased; and the quality of life improvement rate was increased (RR = 1.95; 95%CI: 1.41 to 2.71; P < 0.0001).
The efficacy and safety of endoscopic hemostasis were higher than those of the control group.
Endoscopic hemostasis is an effective treatment for acute GC hemorrhage.
